Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.35 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.35 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23343604 | 0.79 | GRM5 (0.51) | ALDH1A1MEN1TSHRKMT2ACYP1A2 | |
| SCHEMBL28535671 | 0.79 | NOTUM (0.41) | CYP1A2 | |
| SCHEMBL28857109 | 0.77 | CYP1A2 (0.40) | CYP1A2OPRM1 | |
| SCHEMBL873288 | 0.76 | — | — | |
| SCHEMBL21341346 | 0.71 | — | — | |
| SCHEMBL31090011 | 0.70 | CSNK1E (0.34) | — | |
| SCHEMBL23867770 | 0.70 | CYP1A2 (0.33) | ALDH1A1MEN1KMT2ACYP1A2GRM5 | |
| SCHEMBL18170310 | 0.69 | — | — | |
| SCHEMBL28158154 | 0.67 | DRD3 (0.33) | DRD3 | |
| SCHEMBL18975880 | 0.67 | HPGD (0.47) | ALDH1A1CHRNB2CHRNA3CHRNA4CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11045455-B2 | Azetidine derivative, preparation method therefor, and use thereof | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2021-06-29 | — | — | US | disclosed |
| US-11045455-B2 | Azetidine derivative, preparation method therefor, and use thereof | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2021-06-29 | — | — | US | disclosed |
| EP-3360878-B9 | AZETIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD (CN) | 2021-05-05 | — | — | EP | disclosed |
| EP-3360878-B9 | AZETIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD (CN) | 2021-05-05 | — | — | EP | disclosed |
| EP-3360878-B1 | AZETIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO LTD (CN) | 2020-09-16 | — | — | EP | disclosed |
| EP-3360878-B1 | AZETIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO LTD (CN) | 2020-09-16 | — | — | EP | disclosed |
| US-20200147062-A1 | AZETIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2020-05-14 | — | — | US | disclosed |
| US-20200147062-A1 | AZETIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2020-05-14 | — | — | US | disclosed |
| US-10159662-B2 | Azetidine derivative, preparation method therefor, and use thereof | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2018-12-25 | — | — | US | disclosed |
| US-20180289680-A1 | AZETIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2018-10-11 | — | — | US | disclosed |
| WO-2017097224-A1 | AZETIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2017-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11045455-B2 | Azetidine derivative, preparation method therefor, and use thereof | JAK1, JAK2, JAK3 | ALDH1A1 1785/4885CHRNB2 4843/4885CHRNA3 4867/4885 |
| US-20200147062-A1 | AZETIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | JAK1, JAK2, JAK3 | ALDH1A1 1785/4885CHRNB2 4843/4885CHRNA3 4867/4885 |
| US-10159662-B2 | Azetidine derivative, preparation method therefor, and use thereof | JAK1, JAK2, JAK3 | ALDH1A1 1785/4885CHRNB2 4843/4885CHRNA3 4867/4885 |
| US-20180289680-A1 | AZETIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | JAK1, JAK2, JAK3 | ALDH1A1 1785/4885CHRNB2 4843/4885CHRNA3 4867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.